CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Key performance metrics for wide market index funds in retirement include return consistency, volatility, and cost efficiency to monitor progress.
28,290 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
EWZ’s semi-annual payouts are highly dependent on Petrobras and Vale, delivering big checks in buoyant commodity mark...
Biotech stocks surged after news that a polarizing FDA official is stepping down. The rally centers on this biotech’s...
With the CLARITY Act stalled in the Senate, XRP traders await a potential reset. A clearance could alter liquidity an...
New filings reveal a surge of political stock trading in Q1, prompting renewed calls for a ban on individual trades b...
Stocks are riding high on robust earnings, but a looming bear market appears increasingly likely as rate paths and st...
With the Fed set to act this month, a dirt-cheap stock looks attractive amid crosscurrents in the market. Here’s why ...
The AI hype loop is loud, but investors want results. This piece breaks down what mark zuckerberg admitted agents cou...
Soccer's biggest tournament is moving to North America in 2026 with an expanded field and a booming betting market. T...
Six ETFs now cover the entire grid-resilience thesis, from hardware and software to infrastructure and energy metals,...
Carlisle Companies stands out as a strong contender in the building products arena thanks to its diversified mix, dis...
Amazon tops Walmart in 2025 U.S. revenue, marking a historic shift toward tech-powered retail. The milestone could re...